AstraZeneca teams up with N-SIDE for trial work

AstraZeneca facility at The Cove
AstraZeneca facility at the Cove in San Francisco (AstraZeneca)

Britain-based Big Pharma AstraZeneca has penned a new collab with Belgium’s N-SIDE for its clinical studies.

AZ will use N-SIDE’s cloud-based software for its tests, giving it "centralized management, real-time trial monitoring and results visualization," the firm said in a statement.

The company told FierceCRO that: "The N-SIDE Suite for clinical trials supports strategic decision making throughout the clinical trial process, enabling clinical trial managers to future proof their supply chain management while also reducing cost, waste and risk."

Webinar

CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

Specifically, AZ will use the N-SIDE “Supply and Dashboard Apps” to design, plan and monitor their clinical trial supply chain.

John Murray, supply chain transformation lead at AstraZeneca, said: "N-SIDE’s Suite provides a tremendous opportunity for AstraZeneca to collaborate across key areas of clinical development and deliver the best studies for our patients."

"We are proud to further our collaboration with AstraZeneca as they implement the N-SIDE Suite for Clinical Trials to manage their clinical supply chain," stated Jacques Parlongue, N-SIDE CEO.

This new deal builds on the consulting services the firm has done for AstraZeneca’s clinical trial supply optimization since 2017.

Suggested Articles

Contract research bigwig Parexel and Vivek Ramaswamy’s Datavant are deepening their trial tech partnership with a new, multiyear deal.

Charles River signed on to an Alzheimer's UK research consortium.

John Ratliff is leaving his former post as CEO of Covance and moving up to lead the CRO’s parent company LabCorp Diagnostics amid a change at the top.